These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22575440)

  • 1. Circulating sclerostin is elevated in short-term and reduced in long-term SCI.
    Battaglino RA; Sudhakar S; Lazzari AA; Garshick E; Zafonte R; Morse LR
    Bone; 2012 Sep; 51(3):600-5. PubMed ID: 22575440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between sclerostin and bone density in chronic spinal cord injury.
    Morse LR; Sudhakar S; Danilack V; Tun C; Lazzari A; Gagnon DR; Garshick E; Battaglino RA
    J Bone Miner Res; 2012 Feb; 27(2):352-9. PubMed ID: 22006831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status.
    Maïmoun L; Ben Bouallègue F; Gelis A; Aouinti S; Mura T; Philibert P; Souberbielle JC; Piketty M; Garnero P; Mariano-Goulart D; Fattal C
    Bone; 2019 Oct; 127():612-619. PubMed ID: 31351195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin: a candidate biomarker of SCI-induced osteoporosis.
    Morse LR; Sudhakar S; Lazzari AA; Tun C; Garshick E; Zafonte R; Battaglino RA
    Osteoporos Int; 2013 Mar; 24(3):961-8. PubMed ID: 22801952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
    Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
    J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies.
    Battaglino RA; Lazzari AA; Garshick E; Morse LR
    Curr Osteoporos Rep; 2012 Dec; 10(4):278-85. PubMed ID: 22983921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteocytes reflect a pro-inflammatory state following spinal cord injury in a rodent model.
    Metzger CE; Gong S; Aceves M; Bloomfield SA; Hook MA
    Bone; 2019 Mar; 120():465-475. PubMed ID: 30550849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
    Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
    Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
    Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
    J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans.
    Roforth MM; Fujita K; McGregor UI; Kirmani S; McCready LK; Peterson JM; Drake MT; Monroe DG; Khosla S
    Bone; 2014 Feb; 59():1-6. PubMed ID: 24184314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
    Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
    Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum sclerostin increases in healthy adult men during bed rest.
    Spatz JM; Fields EE; Yu EW; Divieti Pajevic P; Bouxsein ML; Sibonga JD; Zwart SR; Smith SM
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1736-40. PubMed ID: 22767636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.
    Mödder UI; Hoey KA; Amin S; McCready LK; Achenbach SJ; Riggs BL; Melton LJ; Khosla S
    J Bone Miner Res; 2011 Feb; 26(2):373-9. PubMed ID: 20721932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.
    Invernizzi M; Carda S; Rizzi M; Grana E; Squarzanti DF; Cisari C; Molinari C; Renò F
    Spinal Cord; 2015 Aug; 53(8):615-20. PubMed ID: 25896346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.
    Ma YH; Schwartz AV; Sigurdsson S; Hue TF; Lang TF; Harris TB; Rosen CJ; Vittinghoff E; Eiriksdottir G; Hauksdottir AM; Siggeirsdottir K; Sigurdsson G; Oskarsdottir D; Napoli N; Palermo L; Gudnason V; Li X
    J Clin Endocrinol Metab; 2014 Dec; 99(12):E2584-90. PubMed ID: 25144629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury.
    Phillips EG; Beggs LA; Ye F; Conover CF; Beck DT; Otzel DM; Ghosh P; Bassit ACF; Borst SE; Yarrow JF
    PLoS One; 2018; 13(3):e0194440. PubMed ID: 29579075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.